The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Temarotene     1,1,4,4-tetramethyl-6-[(E)-1- phenylprop-1...

Synonyms: Temaroteno, Temarotenum, CHEMBL554474, Ro-15-0788, AC1O5L4R, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Arotinoid


High impact information on Arotinoid


Chemical compound and disease context of Arotinoid


Biological context of Arotinoid

  • Both induction and suppression responses show identical kinetics and both processes are half-maximal at 5 nM arotinoid and maximal at 10 nM [8].
  • We examined the binding properties of RARs and RXRs for a series of synthetic retinoids and compared the ligand-binding properties of these arotinoid analogs with their ability to regulate gene expression via the retinoid receptors in a cotransfection assay [14].
  • In rats treated for 3 days with ALLN, arotinoid-induced reduction in cortical bone mineral density measured by peripheral quantitative computed tomography (pQCT) was inhibited by 86.4% (p < 0.05) in rats treated with ALLN 100 mg/kg, i.p., and by 82% in rats treated with 50 mg/kg, i.p. (p < 0.05) [15].
  • The arotinoid did not interact with receptor signal transduction pathways under the control of serum components, such as growth factors as half-maximal inhibiton of growth was similar in HT29-S-B6 cells cultured in the absence or presence of serum [16].
  • Influence of food on the bioavailability of Ro 15-0778 in humans [17].

Anatomical context of Arotinoid


Associations of Arotinoid with other chemical compounds

  • Of all retinoids tested, only arotinoid ethylsulfone caused a drastic increase in EGF binding, while hydrocortisone had no effect [21].
  • Inhibition of oral carcinogenesis by the arotinoid mofarotene (Ro 40-8757) in male F344 rats [22].
  • The chemopreventive effect of dietary administration of a new arotinoid, mofarotene (Ro 40-8757), which contains a morpholine structure in the polar end group, during the initiation phase of 4-nitroquinoline 1-oxide (4-NQO)-induced oral carcinogenesis was investigated in male F344 rats [22].
  • Quantitative analysis of retinoids in biological fluids by high-performance liquid chromatography using column switching. III. Determination of the arotinoid sumarotene and its Z-isomer in human and animal plasma [23].
  • Structural modifications of the arotinoid molecule RO 13-7410 led to a difference in the teratogenic potencies of more than five orders of magnitude in mice in vivo and in micromass cultures of rat embryonic limb bud cells (Kistler et al. 1990) [24].

Gene context of Arotinoid

  • Direct addition of Ro 40-8757 to mouse bone-marrow cells in clonogenic assay cultures containing WEHI-3-conditioned medium plus erythropoietin showed no significant enhancement by the arotinoid [25].
  • The oncogene erbB2 (c-neu) and the growth factor EGF expression were more prominent in the small tumors of the mice treated with arotinoid than in the larger tumors of the control group [26].
  • The experimental treatment modalities, interferon-alpha and retinoids, especially arotinoid, are most effective in early stages of CTCL; in advanced stages, the effectiveness can be increased by combination regimens [27].
  • In this study, the effects of the arotinoid mofarotene on single cell motility and vinculin organization of the highly metastatic melanoma cell line K-1735-M2 were determined [28].
  • Influence of 13-cis retinoic acid and of arotinoid on the cytochrome P-450 system in rat liver [29].

Analytical, diagnostic and therapeutic context of Arotinoid

  • On Northern blot analysis, sPRP cDNA hybridized to RNAs of similar sizes in tracheal cells from cat, rabbit, and lamb. sPRP was not detected in tracheal cells that were cultured with 10(-9) M arotinoid [30].
  • Arotinoid Ro 40-8757 caused marked decrease in the number and branching of mammary ducts, and inhibited mammary tumor development with significant decrease in the incidence, multiplicity, and tumor weights compared to the NTP-2000 diet control [26].
  • Established, palpable and measurable rat mammary tumours, chemically induced by oral administration of 12 mg/animal 7,12-dimethylbenz[a]anthracene, were treated with Ro 15-0778 as a feed-admix in daily doses of 100 mg/kg for 6 weeks and 200 and 400 mg/kg for 9 weeks [31].
  • A non-polar arotinoid, Ro 15-0778, has been investigated for its effect on carcinogen-induced changes in rodent respiratory epithelia in organ culture [32].
  • Sixteen patients - 12 with cutaneous T cell lymphoma (CTCL), 1 with Sézary syndrome, 1 with actinic reticuloid, and 2 with parapsoriasis variegata - were treated with either a new, potent arotinoid alone or with combined etretinate (Tigason) and PUVA therapy (Re-PUVA) [33].


  1. Hypercalcemia induced with an arotinoid in thyroparathyroidectomized rats. New model to study bone resorption in vivo. Trechsel, U., Stutzer, A., Fleisch, H. J. Clin. Invest. (1987) [Pubmed]
  2. Treatment of lichen planus with temarotene. Bollag, W., Ott, F. Lancet (1989) [Pubmed]
  3. Comparison of the therapeutic effects of a new arotinoid, Ro 40-8757, and all-trans- and 13-cis-retinoic acids on rat breast cancer. Teelmann, K., Tsukaguchi, T., Klaus, M., Eliason, J.F. Cancer Res. (1993) [Pubmed]
  4. Effects of arotinoids upon murine embryonal carcinoma cells. Sherman, M.I., Paternoster, M.L., Taketo, M. Cancer Res. (1983) [Pubmed]
  5. Comparative teratogenic activity of cancer chemopreventive retinoidal benzoic acid congeners (arotinoids). Flanagan, J.L., Willhite, C.C., Ferm, V.H. J. Natl. Cancer Inst. (1987) [Pubmed]
  6. Cloning of cDNAs specifying vitamin A-responsive human keratins. Eckert, R.L., Green, H. Proc. Natl. Acad. Sci. U.S.A. (1984) [Pubmed]
  7. Induction of ornithine decarboxylase activity and DNA synthesis in hairless mouse epidermis by retinoids. Connor, M.J., Lowe, N.J. Cancer Res. (1983) [Pubmed]
  8. Coordinate control by vitamin A of keratin gene expression in human keratinocytes. Gilfix, B.M., Eckert, R.L. J. Biol. Chem. (1985) [Pubmed]
  9. Percutaneous retinoid absorption and embryotoxicity. Willhite, C.C., Sharma, R.P., Allen, P.V., Berry, D.L. J. Invest. Dermatol. (1990) [Pubmed]
  10. Histologic changes in the skin of the rhino mouse (hrrhhrrh) induced by retinoids. Ashton, R.E., Connor, M.J., Lowe, N.J. J. Invest. Dermatol. (1984) [Pubmed]
  11. The anti-tumor arotinoid Ro 40-8757 protects bone marrow from the toxic effects of 5-fluorouracil. Eliason, J.F., Inoue, T., Kubota, A., Horii, I., Hartmann, D. Int. J. Cancer (1994) [Pubmed]
  12. Retinoid receptor-specific agonists alleviate experimental glomerulonephritis. Lehrke, I., Schaier, M., Schade, K., Morath, C., Waldherr, R., Ritz, E., Wagner, J. Am. J. Physiol. Renal Physiol. (2002) [Pubmed]
  13. Effects of human recombinant calcitonin on a rat osteopenia model induced by TPTX and arotinoid. Fukuda, C., Oizumi, K., Ohhata, K., Kiyokawa, A., Katsumata, M., Ishikawa, H., Miyamoto, M. Calcif. Tissue Int. (2002) [Pubmed]
  14. Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties. Boehm, M.F., McClurg, M.R., Pathirana, C., Mangelsdorf, D., White, S.K., Hebert, J., Winn, D., Goldman, M.E., Heyman, R.A. J. Med. Chem. (1994) [Pubmed]
  15. Effects of an inhibitor of cathepsin L on bone resorption in thyroparathyroidectomized and ovariectomized rats. Millest, A.J., Breen, S.A., Loveday, B.E., Clarkson, P.N., Simpson, C.A., Waterton, J.C., Johnstone, D. Bone (1997) [Pubmed]
  16. Antiproliferative effects of the arotinoid Ro 40-8757 in human gastrointestinal and pancreatic cancer cell lines: combinations with 5-fluorouracil and interferon-alpha. Louvet, C., Djelloul, S., Forgue-Lafitte, M.E., Mester, J., Zimber, A., Gespach, C. Br. J. Cancer (1996) [Pubmed]
  17. Influence of food on the bioavailability of Ro 15-0778 in humans. Holazo, A.A., Pinili, E.E., De Grazia, F.T., Patel, I.H. Pharm. Res. (1990) [Pubmed]
  18. Down-regulation of mitochondrial gene expression by the anti-tumor arotinoid mofarotene (Ro 40-8757). Uchida, T., Inagaki, N., Furuichi, Y., Eliason, J.F. Int. J. Cancer (1994) [Pubmed]
  19. The arotinoids: early clinical experience and discussion of future development. Arnold, A., Kowaleski, B., Tozer, R., Hirte, H. Leukemia (1994) [Pubmed]
  20. Pharmacokinetics of topically applied radiolabeled retinoids in hairless mouse epidermis and dermis after single applications. Connor, M.J., Lindae, M.L., Lowe, N.J. J. Invest. Dermatol. (1985) [Pubmed]
  21. Effects of retinoids on differentiation, lipid metabolism, epidermal growth factor, and low-density lipoprotein binding in squamous carcinoma cells. Ponec, M., Weerheim, A., Havekes, L., Boonstra, J. Exp. Cell Res. (1987) [Pubmed]
  22. Inhibition of oral carcinogenesis by the arotinoid mofarotene (Ro 40-8757) in male F344 rats. Tanaka, T., Makita, H., Ohnishi, M., Mori, H., Satoh, K., Hara, A. Carcinogenesis (1995) [Pubmed]
  23. Quantitative analysis of retinoids in biological fluids by high-performance liquid chromatography using column switching. III. Determination of the arotinoid sumarotene and its Z-isomer in human and animal plasma. Wyss, R., Bucheli, F. J. Chromatogr. (1992) [Pubmed]
  24. Teratogenicity of arotinoids (retinoids) in the rat whole embryo culture. Bechter, R., Terlouw, G.D., Tsuchiya, M., Tsuchiya, T., Kistler, A. Arch. Toxicol. (1992) [Pubmed]
  25. The anti-tumor arotinoid Ro 40-8757 protects bone marrow from the toxic effects of cyclophosphamide. Eliason, J.F., Inoue, T., Kubota, A., Teelmann, K., Horii, I., Hartmann, D. Int. J. Cancer (1993) [Pubmed]
  26. Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene. Rao, G.N., Ney, E., Herbert, R.A. Breast Cancer Res. Treat. (1999) [Pubmed]
  27. Therapeutic approaches in cutaneous lymphoma. Jörg, B., Kerl, H., Thiers, B.H., Bröcker, E.B., Burg, G. Dermatologic clinics. (1994) [Pubmed]
  28. Mofarotene-induced inhibition of melanoma cell motility by increasing vinculin-containing focal contacts. Helige, C., Hofmann-Wellenhof, R., Fink-Puches, R., Smolle, J. Melanoma Res. (2004) [Pubmed]
  29. Influence of 13-cis retinoic acid and of arotinoid on the cytochrome P-450 system in rat liver. Goerz, G., Hamm, L., Bolsen, K., Merk, H. Dermatologica (1984) [Pubmed]
  30. A small proline-rich protein regulated by vitamin A in tracheal epithelial cells is induced in lung tumors. Tesfaigzi, J., Wright, P.S., Oreffo, V., An, G., Wu, R., Carlson, D.M. Am. J. Respir. Cell Mol. Biol. (1993) [Pubmed]
  31. Therapeutic effect of the arotinoid Ro 15-0778 on chemically induced rat mammary carcinoma. Teelmann, K., Bollag, W. European journal of cancer & clinical oncology. (1988) [Pubmed]
  32. Prevention and reversal by a non-polar arotinoid (Ro 15-0778) of 3,4-benzpyrene- and cigarette smoke condensate-induced hyperplasia and metaplasia of rodent respiratory epithelia grown in vitro. Lasnitzki, I., Bollag, W. European journal of cancer & clinical oncology. (1987) [Pubmed]
  33. Retinoids in cutaneous T cell lymphomas. Mahrle, G., Thiele, B. Dermatologica (1987) [Pubmed]
WikiGenes - Universities